本文選題：坦索羅辛 + 前列金丹片�。� 參考：《山東中醫(yī)藥大學(xué)》2014年碩士論文

【摘要】：目的：本課題選用前列金丹片聯(lián)合鹽酸坦索羅辛緩釋膠囊治療良性前列腺增生癥，觀察其對證候評分、國際前列腺癥狀評分的影響，探討前列金丹片聯(lián)合鹽酸坦索羅辛緩釋膠囊應(yīng)用的臨床療效及安全性。 方法：將臨床診斷為濕熱瘀阻型良性前列腺增生癥的老年患者60例隨機(jī)分為2組，其中單純西藥組30例，口服鹽酸坦索羅辛緩釋膠囊0.2mg，QD；聯(lián)合用藥組30例，聯(lián)合服用鹽酸坦索羅辛緩釋膠囊0.2mg QD和前列金丹片3.24g，TID，兩組均觀察12個月。分別觀察兩組的中醫(yī)證候評分、國際前列腺癥狀評分、生活質(zhì)量評分、殘余尿量、前列腺體積、肝腎功能、血常規(guī)、前列腺特異抗原（PSA）、尿常規(guī)等的變化，進(jìn)行統(tǒng)計分析，判斷療效及安全性。 結(jié)果：臨床觀察發(fā)現(xiàn)，，兩組用藥均能改善患者的癥狀，提高生活質(zhì)量，減少殘余尿量，降低中醫(yī)證候評分、IPSS評分。兩組間比較，聯(lián)合用藥組降低IPSS評分、中醫(yī)證候評分效果優(yōu)于單純西藥組。兩組患者的血常規(guī)、尿常規(guī)、大便常規(guī)、前列腺體積、前列腺抗原、肝功能、腎功能無明顯變化。兩組間比較不良反應(yīng)發(fā)生率無明顯差異。 結(jié)論：臨床觀察結(jié)果表明，前列金丹片聯(lián)合鹽酸坦索羅辛緩釋膠囊對于IPSS評分、中醫(yī)證候評分的影響明顯優(yōu)于單用鹽酸坦索羅辛緩釋膠囊，具有良好的臨床療效及安全性，為良性前列腺增生癥治療選擇提供依據(jù)。
[Abstract]:Objective: to study the effect of Qianlie Jindan tablet combined with Tansulosin hydrochloride sustained-release capsule on benign prostatic hyperplasia (BPH) and to observe its effect on syndrome score and international prostatic symptom score. Objective: to investigate the clinical efficacy and safety of Qianlianjindan tablet combined with tansoloxin hydrochloride sustained-release capsule. Methods: sixty elderly patients with damp-heat stasis type benign prostatic hyperplasia were randomly divided into two groups: the western medicine group (n = 30) and the combination group (n = 30). Tansoloxine hydrochloride sustained release capsule (0.2mg QD) and Qianlie Jindan tablet (3.24 g / TID) were used in both groups for 12 months. The changes of TCM syndrome score, international prostate symptom score, quality of life score, residual urine volume, prostate volume, liver and kidney function, blood routine, prostate specific antigen (PSAA) and urine routine were observed and analyzed statistically. To judge the efficacy and safety. Results: the clinical observation showed that both groups could improve the symptoms, improve the quality of life, reduce the residual urine volume, and reduce the TCM syndrome score and IPSS score. Compared with the two groups, the combined drug group reduced the IPSS score, and the TCM syndrome score was better than that of the western medicine group. The blood routine, urine routine, stool routine, prostate volume, prostate antigen, liver function and renal function were not significantly changed in both groups. There was no significant difference in the incidence of adverse reactions between the two groups. Conclusion: the clinical observation results show that the effect of Qianliejindan tablet combined with Tansoloxin Hydrochloride sustained release capsule on IPSS score and TCM syndrome score is obviously superior to that of Tansoloxin Hydrochloride sustained-release capsule alone. It has good clinical efficacy and safety. To provide the basis for the treatment of benign prostatic hyperplasia.
【學(xué)位授予單位】：山東中醫(yī)藥大學(xué)
【學(xué)位級別】：碩士
【學(xué)位授予年份】：2014
【分類號】：R697.3

【參考文獻(xiàn)】

相關(guān)期刊論文 前10條

1 戚世偉,熊成熙,郎笑梅;金匱腎氣丸防治前列腺增生探析[J];中醫(yī)藥臨床雜志;2004年05期

2 董襄國,吳明清;良性前列腺增生辨證論治[J];中國醫(yī)藥學(xué)報;2004年06期

3 趙建業(yè);戴春福教授以活血法治療前列腺增生癥經(jīng)驗[J];福建中醫(yī)藥;2004年02期

4 鄭清國,陳光強(qiáng);論命門即前列腺[J];福建中醫(yī)學(xué)院學(xué)報;2005年05期

5 張文科;海藻玉壺湯治療前列腺增生98例臨床觀察[J];甘肅中醫(yī);2000年02期

6 趙娜;郭治昕;趙雪;趙利斌;;丹參的化學(xué)成分與藥理作用[J];國外醫(yī)藥(植物藥分冊);2007年04期

7 李軍,呂海香;清熱利濕活血化瘀法治療前列腺增生癥36例[J];廣西中醫(yī)藥;2002年04期

8 盧泓,艾華,陳克軍;補(bǔ)中益氣湯加味治療良性前列腺增生癥33例[J];廣西中醫(yī)藥;2002年06期

9 劉磊;;淺談前列腺增生癥的辨證施治[J];國醫(yī)論壇;2008年04期

10 焦安欽;前列腺增生癥病機(jī)特點與治療思路[J];貴陽中醫(yī)學(xué)院學(xué)報;1996年04期

本文編號：1888342